These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 20105592)

  • 1. Can we preoperatively risk stratify ovarian masses for malignancy?
    Oltmann SC; Garcia N; Barber R; Huang R; Hicks B; Fischer A
    J Pediatr Surg; 2010 Jan; 45(1):130-4. PubMed ID: 20105592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance.
    Oltmann SC; Fischer A; Barber R; Huang R; Hicks B; Garcia N
    J Pediatr Surg; 2010 Jan; 45(1):135-9. PubMed ID: 20105593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian germ cell tumours: a 17-year study in a single unit.
    Panteli C; Curry J; Kiely E; Pierro A; de Coppi P; Anderson J; Sebire N; Drake D
    Eur J Pediatr Surg; 2009 Apr; 19(2):96-100. PubMed ID: 19360543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.
    Antila R; Jalkanen J; Heikinheimo O
    Gynecol Oncol; 2006 Apr; 101(1):97-101. PubMed ID: 16278010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytosis associated with malignant ovarian lesions within a pediatric/adolescent population.
    Haddad LB; Laufer MR
    J Pediatr Adolesc Gynecol; 2008 Oct; 21(5):243-6. PubMed ID: 18794018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum C-reactive protein in the differential diagnosis of ovarian masses.
    Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
    Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
    Roman LD; Muderspach LI; Burnett AF; Morrow CP
    J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period.
    Cass DL; Hawkins E; Brandt ML; Chintagumpala M; Bloss RS; Milewicz AL; Minifee PK; Wesson DE; Nuchtern JG
    J Pediatr Surg; 2001 May; 36(5):693-9. PubMed ID: 11329568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
    Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
    Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian malignancy in breast cancer patients with an adnexal mass.
    Simpkins F; Zahurak M; Armstrong D; Grumbine F; Bristow R
    Obstet Gynecol; 2005 Mar; 105(3):507-13. PubMed ID: 15738016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric ovarian malignancies: how efficacious are current staging practices?
    Oltmann SC; Garcia NM; Barber R; Hicks B; Fischer AC
    J Pediatr Surg; 2010 Jun; 45(6):1096-102. PubMed ID: 20620302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian masses in children and adolescents - an analysis of 521 clinical cases.
    Zhang M; Jiang W; Li G; Xu C
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):e73-7. PubMed ID: 24157281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of surgeon specialty on ovarian-conserving surgery in young females with an adnexal mass.
    Bristow RE; Nugent AC; Zahurak ML; Khouzhami V; Fox HE
    J Adolesc Health; 2006 Sep; 39(3):411-6. PubMed ID: 16919804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.